Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31758219 | 0.84 | DDB1 (0.36) | CRBNDDB1NR1H2USP2SMN1; SMN2 | |
| SCHEMBL1583251 | 0.79 | DDB1 (0.47) | CRBNDDB1NR1H2USP2SMN1; SMN2 | |
| SCHEMBL31218507 | 0.78 | CHRM2 (0.44) | NR1H2USP2SMN1; SMN2BUB1KDM4E | |
| SCHEMBL30872655 | 0.77 | KDM4E (0.37) | CRBNDDB1NR1H2USP2SMN1; SMN2 | |
| SCHEMBL7997935 | 0.77 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPK1 | |
| SCHEMBL4796997 | 0.76 | CHRM2 (0.43) | NR1H2USP2SMN1; SMN2BUB1KDM4E | |
| SCHEMBL23152364 | 0.75 | DDB1 (0.34) | CRBNDDB1NR1H2MAPK1 | |
| SCHEMBL9376793 | 0.74 | MAPK1 (0.41) | CRBNDDB1NR1H2SMN1; SMN2MAPK1 | |
| SCHEMBL12473225 | 0.73 | PDE2A (0.52) | MAPK1 | |
| SCHEMBL22278392 | 0.73 | CCNB2 (0.46) | SMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2023240379-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF | 南京医工医药技术有限公司 | 2023-12-21 | — | — | WO | disclosed |
| CN-106279132-B | 2, 4-imidazoline diketone heterocyclic derivative and preparation method and application thereof | 四川大学华西医院 | 2019-11-26 | — | — | CN | disclosed |
| CN-106279132-A | 2, 4-imidazoline diketone heterocyclic derivative and preparation method and application thereof | 四川大学华西医院 | 2017-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | CRBN 592/4885DDB1 1117/4885NR1H2 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.